

# Ferruccio Bonino

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2366708/publications.pdf>

Version: 2024-02-01

249  
papers

22,463  
citations

17440

63  
h-index

8630

146  
g-index

252  
all docs

252  
docs citations

252  
times ranked

9456  
citing authors

#	ARTICLE	IF	CITATIONS
1	An Assay for Circulating Antibodies to a Major Etiologic Virus of Human Non-A, Non-B Hepatitis. <i>Science</i> , 1989, 244, 362-364.	12.6	3,478
2	Peginterferon Alfa-2a Alone, Lamivudine Alone, and the Two in Combination in Patients with HBeAg-Negative Chronic Hepatitis B. <i>New England Journal of Medicine</i> , 2004, 351, 1206-1217.	27.0	1,082
3	A proposed system for the nomenclature of hepatitis C viral genotypes. <i>Hepatology</i> , 1994, 19, 1321-1324.	7.3	962
4	Immunofluorescence detection of new antigen-antibody system (delta/anti-delta) associated to hepatitis B virus in liver and in serum of HBsAg carriers.. <i>Gut</i> , 1977, 18, 997-1003.	12.1	879
5	Detection of hepatitis C viral sequences in non-A, non-B hepatitis. <i>Lancet, The</i> , 1990, 335, 1-3.	13.7	818
6	Evidence for immune selection of hepatitis C virus (HCV) putative envelope glycoprotein variants: potential role in chronic HCV infections.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1992, 89, 3468-3472.	7.1	723
7	Variable and hypervariable domains are found in the regions of HCV corresponding to the flavivirus envelope and NS1 proteins and the pestivirus envelope glycoproteins. <i>Virology</i> , 1991, 180, 842-848.	2.4	641
8	Transient elastography: a new surrogate marker of liver fibrosis influenced by major changes of transaminases. <i>Journal of Viral Hepatitis</i> , 2007, 14, 360-369.	2.0	573
9	Inhibition of Natural Killer Cells through Engagement of CD81 by the Major Hepatitis C Virus Envelope Protein. <i>Journal of Experimental Medicine</i> , 2002, 195, 35-42.	8.5	420
10	Hepatitis B virus surface antigen levels: A guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. <i>Hepatology</i> , 2009, 49, 1141-1150.	7.3	418
11	Hepatitis B Surface Antigen Serum Levels Help to Distinguish Active From Inactive Hepatitis B Virus Genotype D Carriers. <i>Gastroenterology</i> , 2010, 139, 483-490.	1.3	361
12	Wild-type and e antigen-minus hepatitis B viruses and course of chronic hepatitis.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1991, 88, 4186-4190.	7.1	360
13	Chronic Hepatitis in Carriers of Hepatitis B Surface Antigen, with Intrahepatic Expression of the Delta Antigen. <i>Annals of Internal Medicine</i> , 1983, 98, 437.	3.9	351
14	Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. <i>Hepatology</i> , 2006, 44, 1543-1554.	7.3	347
15	T-lymphocyte response to hepatitis C virus in different clinical courses of infection. <i>Gastroenterology</i> , 1993, 104, 580-587.	1.3	331
16	Chronic hepatitis in HBsAg carriers with serum HBV-DNA and Anti-HBe. <i>Gastroenterology</i> , 1986, 90, 1268-1273.	1.3	330
17	Hepatitis B virus DNA in the sera of HBsAg carriers: A marker of active hepatitis B virus replication in the liver. <i>Hepatology</i> , 1981, 1, 386-391.	7.3	312
18	Hepatitis delta virus: protein composition of delta antigen and its hepatitis B virus-derived envelope. <i>Journal of Virology</i> , 1986, 58, 945-950.	3.4	294

#	ARTICLE	IF	CITATIONS
19	Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study. <i>Journal of Hepatology</i> , 2002, 36, 263-270.	3.7	290
20	Sustained Response of Hepatitis B e Antigen-Negative Patients 3 Years After Treatment with Peginterferon Alfa-2a. <i>Gastroenterology</i> , 2009, 136, 2169-2179.e4.	1.3	288
21	Effect of interferon- $\alpha$ on progression of cirrhosis to hepatocellular carcinoma: a retrospective cohort study. <i>Lancet, The</i> , 1998, 351, 1535-1539.	13.7	280
22	AISF position paper on nonalcoholic fatty liver disease (NAFLD): Updates and future directions. <i>Digestive and Liver Disease</i> , 2017, 49, 471-483.	0.9	254
23	Compartmentalization of T lymphocytes to the site of disease: intrahepatic CD4+ T cells specific for the protein NS4 of hepatitis C virus in patients with chronic hepatitis C.. <i>Journal of Experimental Medicine</i> , 1993, 178, 17-25.	8.5	246
24	Predicting response to peginterferon $\alpha$ -2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B. <i>Gut</i> , 2007, 56, 699-705.	12.1	240
25	Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: Final long-term results. <i>Liver Transplantation</i> , 2007, 13, 349-360.	2.4	239
26	A new hepatitis B virus strain in patients with severe anti-HBe positive chronic hepatitis B. <i>Journal of Hepatology</i> , 1990, 10, 258-261.	3.7	233
27	Natural course and response to interferon of chronic hepatitis B accompanied by antibody to hepatitis B e antigen. <i>Hepatology</i> , 1989, 10, 198-202.	7.3	230
28	Transmission of the hepatitis B virus-associated delta agent to the eastern woodchuck.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1984, 81, 2208-2212.	7.1	193
29	Hepatitis B virus unable to secrete e antigen and response to interferon in chronic hepatitis B. <i>Gastroenterology</i> , 1993, 105, 845-850.	1.3	190
30	Immunotherapy of HCC metastases with autologous T cell receptor redirected T cells, targeting HBsAg in a liver transplant patient. <i>Journal of Hepatology</i> , 2015, 62, 486-491.	3.7	160
31	Decompensated Chronic Heart Failure: Increased Liver Stiffness Measured by Means of Transient Elastography. <i>Radiology</i> , 2010, 257, 872-878.	7.3	155
32	Detection of intrahepatic replication of hepatitis C virus RNA by in situ hybridization and comparison with histopathology.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1992, 89, 2247-2251.	7.1	153
33	Patterns of hepatitis delta virus reinfection and disease in liver transplantation. <i>Gastroenterology</i> , 1991, 101, 1649-1655.	1.3	151
34	Long-term follow-up of patients with chronic hepatitis C treated with different doses of interferon- $\alpha$ 2b. <i>Hepatology</i> , 1993, 18, 1300-1305.	7.3	149
35	Infectious Hepatitis B Virus Variant Defective in Pre-S2 Protein Expression in a Chronic Carrier. <i>Virology</i> , 1993, 194, 137-148.	2.4	141
36	Delta hepatitis agent: structural and antigenic properties of the delta-associated particle. <i>Infection and Immunity</i> , 1984, 43, 1000-1005.	2.2	140

#	ARTICLE	IF	CITATIONS
37	Hepatitis B surface antigen levels: association with 5-year response to peginterferon alfa-2a in hepatitis B e-antigen-negative patients. <i>Hepatology International</i> , 2013, 7, 88-97.	4.2	136
38	A proposed system for the nomenclature of hepatitis C viral genotypes. <i>Hepatology</i> , 1994, 19, 1321-1324.	7.3	136
39	Prevention of recurrent hepatitis C after liver transplantation with early interferon and ribavirin treatment. <i>Transplantation Proceedings</i> , 2001, 33, 1355-1357.	0.6	127
40	Pathophysiology of Non Alcoholic Fatty Liver Disease. <i>International Journal of Molecular Sciences</i> , 2016, 17, 2082.	4.1	126
41	Type D hepatitis: The clinical significance of hepatitis D virus RNA in serum as detected by a hybridization-based assay. <i>Hepatology</i> , 1986, 6, 1297-1302.	7.3	122
42	Liver stiffness in the hepatitis B virus carrier: A non-invasive marker of liver disease influenced by the pattern of transaminases. <i>World Journal of Gastroenterology</i> , 2008, 14, 6154.	3.3	116
43	Hepatitis G virus RNA in the serum of patients with elevated gamma glutamyl transpeptidase and alkaline phosphatase: a specific liver disease. <i>Journal of Viral Hepatitis</i> , 1996, 3, 301-306.	2.0	113
44	Human CD4+ T-cell response to hepatitis delta virus: identification of multiple epitopes and characterization of T-helper cytokine profiles. <i>Journal of Virology</i> , 1997, 71, 2241-2251.	3.4	101
45	Comparable functions of plasmacytoid and monocyte-derived dendritic cells in chronic hepatitis C patients and healthy donors. <i>Journal of Hepatology</i> , 2005, 42, 61-67.	3.7	97
46	A controlled trial of human lymphoblastoid interferon in chronic hepatitis B in Italy. <i>Hepatology</i> , 1989, 10, 336-341.	7.3	96
47	Hepatitis B virus replication modulates pathogenesis of hepatitis D virus in chronic hepatitis D. <i>Hepatology</i> , 1991, 13, 413-416.	7.3	96
48	Prophylaxis against HCV recurrence after liver transplantation: Effect of interferon and ribavirin combination. <i>Transplantation Proceedings</i> , 1997, 29, 519-521.	0.6	92
49	Human immunodeficiency virus infection as risk factor for mother-to-child hepatitis C virus transmission; Persistence of anti-hepatitis C virus in children is associated with the mother's anti-hepatitis C virus immunoblotting pattern. <i>Hepatology</i> , 1995, 21, 328-332.	7.3	91
50	The $\delta$ agent: HBsAg particles with $\delta$ antigen and RNA in the serum of an HBV carrier. <i>Hepatology</i> , 1981, 1, 127-131.	7.3	89
51	Response to peginterferon alfa-2a (40KD) in HBeAg-negative CHB: On-treatment kinetics of HBsAg serum levels vary by HBV genotype. <i>Journal of Hepatology</i> , 2013, 59, 1153-1159.	3.7	88
52	A histological study of hepatitis delta virus liver disease. <i>Hepatology</i> , 1986, 6, 1303-1307.	7.3	84
53	Hepatic endoplasmic reticulum storage diseases. <i>Liver</i> , 1992, 12, 357-362.	0.1	84
54	Hepatitis B virus unable to secrete E antigen. <i>Gastroenterology</i> , 1991, 100, 1138-1141.	1.3	81

#	ARTICLE	IF	CITATIONS
55	Monitoring the natural course and response to therapy of chronic hepatitis B with an automated semi-quantitative assay for IgM anti-HBc. <i>Journal of Hepatology</i> , 1993, 19, 431-436.	3.7	80
56	Delta hepatitis in inapparent carriers of hepatitis B surface antigen. <i>Gastroenterology</i> , 1983, 85, 669-673.	1.3	78
57	Rapidly progressive HBsAg-positive hepatitis in Italy. <i>Journal of Hepatology</i> , 1987, 5, 274-281.	3.7	78
58	Diagnosis of Budd-Chiari syndrome by pulsed Doppler ultrasound. <i>Gastroenterology</i> , 1991, 100, 1324-1331.	1.3	78
59	Hepatitis B Virus Mutants. <i>Intervirology</i> , 1999, 42, 69-80.	2.8	73
60	Recombinant interferon- $\alpha$ 2a hastens the rate of HBeAg clearance in children with chronic hepatitis B. <i>Hepatology</i> , 1994, 20, 287-290.	7.3	70
61	Chronic HDV (hepatitis delta virus) hepatitis. <i>Journal of Hepatology</i> , 1988, 6, 8-14.	3.7	66
62	Acute alcoholic hepatitis, end stage alcoholic liver disease and liver transplantation: An Italian position statement. <i>World Journal of Gastroenterology</i> , 2014, 20, 14642.	3.3	66
63	INHIBITION OF HEPATITIS B VIRUS REPLICATION BY VIDARABINE MONOPHOSPHATE CONJUGATED WITH LACTOSAMINATED SERUM ALBUMIN. <i>Lancet, The</i> , 1988, 332, 13-15.	13.7	65
64	Relevance of inapparent coinfection by hepatitis B virus in alpha interferon-treated patients with hepatitis C virus chronic hepatitis. <i>Journal of Medical Virology</i> , 1997, 51, 313-318.	5.0	63
65	Role of hepatitis delta virus infection in hepatocellular carcinoma. <i>Digestive Diseases and Sciences</i> , 1991, 36, 1134-1136.	2.3	62
66	The epidemiology of hepatitis delta infection in Italy. <i>Journal of Hepatology</i> , 1992, 15, 211-215.	3.7	62
67	High prevalence of autoimmune phenomena in hepatitis C virus antibody positive patients with lymphoproliferative and connective tissue disorders. <i>British Journal of Haematology</i> , 1996, 95, 204-211.	2.5	62
68	Chronic hepatitis B e antigen (HBeAg) negative, anti-HBe positive hepatitis B: an overview. <i>Journal of Hepatology</i> , 2003, 39, 160-163.	3.7	60
69	HEPATITIS C VIRUS: A POSSIBLE CAUSE OF CHRONIC HEPATITIS IN ALCOHOLICS. <i>Lancet, The</i> , 1989, 334, 1390-1391.	13.7	58
70	Circulating Hepatitis B Surface Antigen Particles Carry Hepatocellular microRNAs. <i>PLoS ONE</i> , 2012, 7, e31952.	2.5	58
71	Fluctuations in viremia, aminotransferases and IgM antibody to hepatitis B core antigen in chronic hepatitis B patients with disease exacerbations. <i>Liver</i> , 1994, 14, 175-181.	0.1	57
72	Detection of HBV-DNA by in situ hybridization using a biotin-labeled probe. <i>Journal of Medical Virology</i> , 1985, 15, 373-382.	5.0	56

#	ARTICLE	IF	CITATIONS
73	A precore-defective mutant of hepatitis B virus associated with e antigen-negative chronic liver disease. <i>Journal of Medical Virology</i> , 1990, 32, 109-118.	5.0	56
74	Ribavirin treatment for chronic hepatitis D: a pilot study. <i>Liver</i> , 1994, 14, 154-157.	0.1	56
75	Practice guidelines for the treatment of hepatitis C: Recommendations from an AISF/SIMIT/SIMAST Expert Opinion Meeting. <i>Digestive and Liver Disease</i> , 2010, 42, 81-91.	0.9	56
76	A "systems medicine" approach to the study of non-alcoholic fatty liver disease. <i>Digestive and Liver Disease</i> , 2016, 48, 333-342.	0.9	56
77	Adenine arabinoside monophosphate and acyclovir monophosphate coupled to lactosaminated albumin reduce woodchuck hepatitis virus viremia at doses lower than do the unconjugated drugs. <i>Hepatology</i> , 1991, 14, 16-24.	7.3	55
78	A novel method for banking dental pulp stem cells. <i>Transfusion and Apheresis Science</i> , 2012, 47, 199-206.	1.0	51
79	Long-term outcome of inactive and active, low viraemic HBsAg-negative hepatitis B virus infection: Benign course towards HBsAg clearance. <i>Liver International</i> , 2017, 37, 1622-1631.	3.9	51
80	Long Term Response to Therapy of Chronic Anti-HBe-Positive Hepatitis B Is Poor Independent of Type and Schedule of Interferon. <i>American Journal of Gastroenterology</i> , 1999, 94, 1366-1372.	0.4	50
81	Replicating and virion secreting hepatitis B mutant virus unable to produce preS2 protein. <i>Journal of Hepatology</i> , 1991, 13, S102-S104.	3.7	49
82	Sequence variation in hepatitis C viral isolates. <i>Journal of Hepatology</i> , 1991, 13, S6-S14.	3.7	49
83	Adenine arabinoside monophosphate coupled to lactosaminated human albumin administered for 4 weeks in patients with chronic type B hepatitis decreased viremia without producing significant side effects. <i>Hepatology</i> , 1996, 23, 657-661.	7.3	49
84	Long term response to therapy of chronic anti-HBe-positive Hepatitis B is poor independent of type and schedule of interferon. <i>American Journal of Gastroenterology</i> , 1999, 94, 1366-1372.	0.4	48
85	Hepatitis B virus DNA (HBV-DNA) in anti-HBe positive sera. <i>Liver</i> , 1984, 4, 177-183.	0.1	48
86	A Multiphase Model of the Dynamics of HBV Infection in Hbeag-Negative Patients during Pegylated Interferon- $\alpha$ 2A, Lamivudine and Combination Therapy. <i>Antiviral Therapy</i> , 2006, 11, 197-212.	1.0	46
87	Liver targeting of antiviral nucleoside analogues through the asialoglycoprotein receptor. <i>Journal of Viral Hepatitis</i> , 1997, 4, 363-370.	2.0	45
88	Total Hepatitis B Core Antigen Antibody, a Quantitative Non-Invasive Marker of Hepatitis B Virus Induced Liver Disease. <i>PLoS ONE</i> , 2015, 10, e0130209.	2.5	45
89	Familiar clustering and spreading of hepatitis delta virus infection. <i>Journal of Hepatology</i> , 1985, 1, 221-226.	3.7	44
90	EFFECTS OF A BICARBONATE-ALKALINE MINERAL WATER ON GASTRIC FUNCTIONS AND FUNCTIONAL DYSPEPSIA: A PRECLINICAL AND CLINICAL STUDY. <i>Pharmacological Research</i> , 2002, 46, 525-531.	7.1	44

#	ARTICLE	IF	CITATIONS
91	Serial passage of hepatitis delta virus in chronic hepatitis B virus carrier chimpanzees. <i>Hepatology</i> , 1988, 8, 1655-1661.	7.3	43
92	Impaired response to alpha interferon in patients with an inapparent hepatitis B and hepatitis C virus coinfection. <i>Archives of Virology</i> , 1997, 142, 535-544.	2.1	43
93	Continuous versus intermittent therapy for chronic hepatitis C with recombinant interferon alfa-2a. <i>Gastroenterology</i> , 1994, 107, 479-485.	1.3	42
94	Treatment of mild non-chemotherapy-induced iron deficiency anemia in cancer patients: Comparison between oral ferrous bisglycinate chelate and ferrous sulfate. <i>Biomedicine and Pharmacotherapy</i> , 2012, 66, 414-418.	5.6	41
95	A Serum MicroRNA Signature Is Associated with the Immune Control of Chronic Hepatitis B Virus Infection. <i>PLoS ONE</i> , 2014, 9, e110782.	2.5	41
96	Treatment of chronic delta hepatitis with $\hat{1}\pm$ -2 recombinant interferon. <i>Journal of Hepatology</i> , 1986, 3, S229-S233.	3.7	40
97	Colon cancer seeding after percutaneous fine needle aspiration of liver metastasis. <i>Journal of Hepatology</i> , 1993, 18, 276-278.	3.7	39
98	Quantitative analysis of IgM anti-HBc in chronic hepatitis B patients using a new "gray-zone" for the evaluation of "borderline" values. <i>Journal of Hepatology</i> , 1996, 25, 644-648.	3.7	39
99	Identification of New Autoantigens by Protein Array Indicates a Role for IL4 Neutralization in Autoimmune Hepatitis. <i>Molecular and Cellular Proteomics</i> , 2012, 11, 1885-1897.	3.8	38
100	Hepatitis Delta Virus Infection of the Liver: Progress in Virology, Pathobiology, and Diagnosis. <i>Seminars in Liver Disease</i> , 1988, 8, 350-356.	3.6	37
101	Cytoplasmic Tubular Structures in Liver of HBsAg Carrier Chimpanzees Infected with Delta Agent and Comparison with Cytoplasmic Structures in Non-A, Non-B Hepatitis. <i>Hepatology</i> , 2007, 3, 631-637.	7.3	37
102	Is high AgNOR quantity in hepatocytes associated with increased risk of hepatocellular carcinoma in chronic liver disease?. <i>Journal of Clinical Pathology</i> , 1993, 46, 727-729.	2.0	35
103	A new hepatitis C virus-like flavivirus in patients with cryptogenic liver disease associated with elevated GGT and alkaline phosphatase serum levels. <i>Journal of Viral Hepatitis</i> , 1997, 4, 55-60.	2.0	35
104	Multicenter Evaluation of the Elecsys Hepatitis B Surface Antigen Quantitative Assay. <i>Vaccine Journal</i> , 2011, 18, 1943-1950.	3.1	35
105	The importance of hepatitis B viral DNA in serum and liver. <i>Journal of Hepatology</i> , 1986, 3, 136-141.	3.7	34
106	Delta Agent (Type D) Hepatitis. <i>Seminars in Liver Disease</i> , 1986, 6, 28-33.	3.6	34
107	Intrahepatic markers of hepatitis delta virus infection: A study by in Situ hybridization. <i>Hepatology</i> , 1989, 10, 916-920.	7.3	34
108	Treatment of HBeAg-negative chronic hepatitis B with interferon or pegylated interferon. <i>Journal of Hepatology</i> , 2003, 39, 164-167.	3.7	34

#	ARTICLE	IF	CITATIONS
109	T cell receptor-therapy in HBV-related hepatocellularcarcinoma. <i>Oncolmmunology</i> , 2015, 4, e1008354.	4.6	34
110	Liver Stiffness, a Non-Invasive Marker of Liver Disease: A Core Study Group Report. <i>Antiviral Therapy</i> , 2010, 15, 69-78.	1.0	33
111	Levamisole and Chronic Delta Hepatitis. <i>Annals of Internal Medicine</i> , 1983, 98, 1024.	3.9	32
112	Viral load 1 week after liver transplantation, donor age and rejections correlate with the outcome of recurrent hepatitis C. <i>Liver International</i> , 2007, 27, 612-619.	3.9	30
113	Diagnostic Markers of Chronic Hepatitis B Infection and Disease. <i>Antiviral Therapy</i> , 2010, 15, 35-44.	1.0	29
114	Sustained Response to Interferon+Ribavirin Combination Therapy Predicted by a Model of Hepatitis C Virus Dynamics Using Both Hcv Rna and Alanine Aminotransferase. <i>Antiviral Therapy</i> , 2003, 8, 519-530.	1.0	29
115	Riboprobe assay for HDV RNA: A sensitive method for the detection of the HDV genome in clinical serum samples. <i>Journal of Medical Virology</i> , 1990, 30, 20-24.	5.0	28
116	Subthreshold mania as predictor of depression during interferon treatment in HCV+ patients without current or lifetime psychiatric disorders. <i>Journal of Psychosomatic Research</i> , 2007, 62, 349-355.	2.6	27
117	Hepatotoxicity of intravenous Cyclosporin A in patients with acute ulcerative colitis on total parenteral nutrition. <i>Liver</i> , 1995, 15, 320-323.	0.1	26
118	Propafenone-induced liver injury: Report of a case and review of the literature. <i>Gastroenterology</i> , 1993, 104, 1524-1526.	1.3	25
119	Complement fixing hepatitis B core antigen immune complexes in the liver of patients with HBs antigen positive chronic disease.. <i>Gut</i> , 1976, 17, 837-843.	12.1	24
120	Serum markers of hepatitis B virus replication, liver histology and intrahepatic expression of hepatitis B core antigen. <i>Journal of Hepatology</i> , 1988, 7, 14-20.	3.7	24
121	Hepatitis B virus heterogeneity, one of many factors influencing the severity of hepatitis B. <i>Journal of Hepatology</i> , 1993, 18, 5-8.	3.7	24
122	Hepatitis type C after orthotopic liver transplantation: reinfection and disease recurrence. <i>Journal of Hepatology</i> , 1994, 21, 961-965.	3.7	24
123	Interferon Therapy of Chronic Hepatitis B. <i>Intervirolgy</i> , 2014, 57, 163-170.	2.8	24
124	Treatment with interferon of chronic hepatitis B associated with antibody to hepatitis B e antigen. <i>Journal of Hepatology</i> , 1991, 13, S8-S11.	3.7	23
125	Inhibition of hepatitis B virus replication by adenine arabinoside monophosphate coupled to lactosaminated albumin. Efficacy and minimal active dose. <i>Journal of Hepatology</i> , 1994, 20, 307-309.	3.7	23
126	Gene Expression Profiling Reveals Multiple Protective Influences of the Peptide Î±-Melanocyte-Stimulating Hormone in Experimental Heart Transplantation. <i>Journal of Immunology</i> , 2005, 175, 3391-3401.	0.8	23



#	ARTICLE	IF	CITATIONS
127	Emergence of hepatitis B virus quasispecies with lower susceptibility to nucleos(t)ide analogues during lamivudine treatment. <i>Journal of Antimicrobial Chemotherapy</i> , 2007, 60, 341-349.	3.0	22
128	Severe liver disease is caused by HBV rather than HCV in children with hematological malignancies. <i>The Hematology Journal</i> , 2003, 4, 321-327.	1.4	22
129	Hepatitis C Virus Heteroduplex Tracking Assay for Genotype Determination Reveals Diverging Genotype 2 Isolates in Italian Hemodialysis Patients. <i>Journal of Clinical Microbiology</i> , 1998, 36, 227-233.	3.9	22
130	Alteration in the Transcriptional Profile of Livers from Brain-dead Organ Donors. <i>Transplantation</i> , 2006, 82, 69-79.	1.0	20
131	New immunoassays for total, IgA and IgM antibodies against hepatitis E virus: Prevalence in Italian blood donors and patients with chronic liver or kidney diseases. <i>Digestive and Liver Disease</i> , 2016, 48, 536-541.	0.9	20
132	Complexes of hepatitis B surface antigen and immunoglobulin M in the sera of patients with hepatitis B virus infection. <i>Infection and Immunity</i> , 1983, 41, 950-958.	2.2	20
133	Reduced Expression of the Melanocortin-1 Receptor in Human Liver during Brain Death. <i>NeuroImmunoModulation</i> , 2006, 13, 51-55.	1.8	19
134	Hepatitis C virus markers in patients with long-term biochemical and histological remission of chronic hepatitis. <i>Liver</i> , 1994, 14, 65-70.	0.1	19
135	<i><sc>HCV E1E</sc>2<sc>MF</sc>59</i> vaccine in chronic hepatitis <sc>C</sc> patients treated with <sc>PEG</sc>â€<sc>IFN</sc>1±2a and <sc>R</sc>ibavirin: a randomized controlled trial. <i>Journal of Viral Hepatitis</i> , 2014, 21, 458-465.	2.0	19
136	Treatment of Chronic Hepatitis B: From Research to Clinical Practice Via the Consensus Conferences. <i>Current Pharmaceutical Design</i> , 2004, 10, 2063-2075.	1.9	19
137	Bio-mathematical models of viral dynamics to tailor antiviral therapy in chronic viral hepatitis. <i>World Journal of Gastroenterology</i> , 2009, 15, 531.	3.3	19
138	Superimposed hepatitis and the effect on viral replication in chronic hepatitis B. <i>Journal of Hepatology</i> , 1986, 3, S35-S341.	3.7	18
139	Hepatitis delta virus heterogeneity: a study by immunofluorescence. <i>Journal of Hepatology</i> , 1991, 13, S125-S129.	3.7	18
140	Detection of hepatitis delta virus RNA by a nonradioactive in situ hybridization procedure. <i>Human Pathology</i> , 1992, 23, 557-561.	2.0	18
141	Precore Mutant Hepatitis B Virus and Outcome of Chronic Infection and Hepatitis in Hepatitis B e Antigen-Positive Children. <i>Pediatric Research</i> , 1994, 36, 347-350.	2.3	18
142	Quantitative analysis of wild-type and HBeAg minus hepatitis B viruses by a sequence-dependent primer extension assay. <i>Journal of Medical Virology</i> , 1994, 43, 310-315.	5.0	18
143	IgM antibody against measles virus in patients with inflammatory bowel disease: a marker of virus-related disease?. <i>European Journal of Gastroenterology and Hepatology</i> , 1997, 9, 661-663.	1.6	18
144	Detection of human androgen receptor mRNA in hepatocellular carcinoma by <i>in situ</i> hybridisation. <i>Liver</i> , 1994, 14, 213-219.	0.1	18

#	ARTICLE	IF	CITATIONS
145	Digital liver biopsy: Bio-imaging of fatty liver for translational and clinical research. <i>World Journal of Hepatology</i> , 2018, 10, 231-245.	2.0	18
146	Hepatitis C virus infection and disease. <i>Journal of Hepatology</i> , 1993, 17, S78-S82.	3.7	17
147	Impact of interferon- $\alpha$ therapy on the development of hepatocellular carcinoma in patients with liver cirrhosis: results of an international survey. <i>Journal of Viral Hepatitis</i> , 1997, 4, 79-82.	2.0	17
148	Genome-Wide Comparison of Next-Generation Sequencing and qPCR Platforms for microRNA Profiling in Serum. <i>Methods in Molecular Biology</i> , 2017, 1580, 21-44.	0.9	17
149	Modeling the time-related fluctuations of AFP and PIVKA-II serum levels in patients with cirrhosis undergoing surveillance for hepatocellular carcinoma. <i>Cancer Biomarkers</i> , 2020, 29, 189-196.	1.7	17
150	Serological diagnosis of hepatitis B and delta virus (HBV/HDV) coinfection. <i>Journal of Hepatology</i> , 1991, 12, 10-13.	3.7	16
151	Steato-Score: Non-Invasive Quantitative Assessment of Liver Fat by Ultrasound Imaging. <i>Ultrasound in Medicine and Biology</i> , 2018, 44, 1585-1596.	1.5	16
152	Hepatitis Delta virus, a model of liver cell pathology. <i>Journal of Hepatology</i> , 1991, 13, 260-266.	3.7	15
153	High prevalence of G1 and G2 TT-virus infection in subjects with high and low blood exposure risk: identification of G4 isolates in Italy. <i>Journal of Hepatology</i> , 1999, 31, 990-996.	3.7	15
154	Early and Accurate Prediction of Peg-IFNs/Ribavirin Therapy Outcome in the Individual Patient With Chronic Hepatitis C by Modeling the Dynamics of the Infected Cells. <i>Clinical Pharmacology and Therapeutics</i> , 2008, 84, 212-215.	4.7	15
155	Long-term follow-up of patients with chronic hepatitis C treated with different doses of interferon- $\alpha$ 2b. <i>Hepatology</i> , 1993, 18, 1300-1305.	7.3	15
156	A multiphase model of the dynamics of HBV infection in HBeAg-negative patients during pegylated interferon-alpha2a, lamivudine and combination therapy. <i>Antiviral Therapy</i> , 2006, 11, 197-212.	1.0	15
157	Complexes between hbsag and igm in serum of patients with acute hepatitis. <i>Journal of Medical Virology</i> , 1983, 11, 139-145.	5.0	14
158	Primary biliary cirrhosis: lung involvement. <i>Liver</i> , 1995, 15, 196-201.	0.1	14
159	Individualized treatment of HBeAg-negative CHB using peg-interferon alfa-2a as first-line and week 12 HBV-DNA/HBsAg stopping rule. A cost-effectiveness analysis. <i>Antiviral Therapy</i> , 2013, 18, 623-633.	1.0	14
160	A solid-phase enzyme immunoassay (EIA) for detection of HBeAg and anti-HBe. <i>Journal of Immunological Methods</i> , 1980, 33, 195-200.	1.4	13
161	Detection of hepatitis C virus RNA by reverse-transcriptase and polymerase chain reaction: clinical applications of quantitative analysis. <i>Clinical and Diagnostic Virology</i> , 1994, 1, 289-297.	1.7	13
162	The spectrum of complement-fixing antinuclear antibodies in patients with hepatocellular carcinoma. <i>Hepatology</i> , 1985, 5, 548-555.	7.3	12

#	ARTICLE	IF	CITATIONS
163	Coupling to lactosaminated poly-L-lysine reduces the toxic effects of ribavirin on red blood cells. <i>Journal of Hepatology</i> , 1998, 29, 1032-1033.	3.7	12
164	Increasing serum levels of IgM anti-HCV are diagnostic of recurrent hepatitis C in liver transplant patients with ALT flares. <i>Journal of Viral Hepatitis</i> , 2003, 10, 168-173.	2.0	12
165	Sustained response to interferon-ribavirin combination therapy predicted by a model of hepatitis C virus dynamics using both HCV RNA and alanine aminotransferase. <i>Antiviral Therapy</i> , 2003, 8, 519-30.	1.0	11
166	Expression of estrogen receptor mRNA in tumorous and non-tumorous liver tissue as detected by in situ hybridization. <i>Journal of Surgical Oncology</i> , 1993, 53, 14-17.	1.7	10
167	Treatment of patients with chronic hepatitis C and cirrhosis. <i>Journal of Hepatology</i> , 1999, 31, 197-200.	3.7	10
168	Recombinant interferon- $\alpha$ 2a hastens the rate of HBeAg clearance in children with chronic hepatitis B. <i>Hepatology</i> , 1994, 20, 287-290.	7.3	10
169	Antibodies to Hepatitis C Virus in Kidney Transplantation. <i>Nephron</i> , 1992, 61, 276-277.	1.8	9
170	Prevalence of breakthrough in chronic hepatitis C patients undergoing antiviral therapy: role of type and schedule of alpha interferon. <i>Journal of Hepatology</i> , 1997, 26, 449-450.	3.7	9
171	Triple therapy with first-generation Protease Inhibitors for patients with genotype 1 chronic hepatitis C: Recommendations of the Italian Association for the Study of the Liver (AISF). <i>Digestive and Liver Disease</i> , 2014, 46, 18-24.	0.9	9
172	Leptin resistance before and after obesity: evidence that tissue glucose uptake underlies adipocyte enlargement and liver steatosis/steatohepatitis in Zucker rats from early-life stages. <i>International Journal of Obesity</i> , 2022, 46, 50-58.	3.4	9
173	Problems in diagnosing viral hepatitis.. <i>Gut</i> , 1993, 34, S36-S38.	12.1	8
174	Quantitative detection of hepatitis C virus RNA in the serum of patients with chronic hepatitis C treated with interferon: A pilot study. <i>Clinical and Diagnostic Virology</i> , 1997, 8, 63-70.	1.7	8
175	HBV pre-core mutant in genotype D infected children is selected during HBeAg/anti-HBe seroconversion and leads to HBeAg negative chronic hepatitis B in adulthood. <i>Journal of Medical Virology</i> , 2018, 90, 1232-1239.	5.0	8
176	Natural Killer Response to Exogenous Interferon in Delta Hepatitis: Boost or Depression Defined within the First Week of Therapy. <i>Digestion</i> , 1987, 37, 51-58.	2.3	7
177	Immunohistochemical research on HDV infection in Chinese patients with chronic liver disease. <i>Journal of Tongji Medical University</i> , 1989, 9, 5-7.	0.1	7
178	Thermal Care of Functional Dyspepsia Based on Bicarbonate-Sulphate-Calcium Water: A Sequential Clinical Trial. <i>Evidence-based Complementary and Alternative Medicine</i> , 2007, 4, 381-391.	1.2	7
179	Incidence and Significance of Different Types of Connective Tissue Antibodies in Adult and Pediatric Gastroenterological Disorders. <i>Digestion</i> , 1978, 17, 29-37.	2.3	6
180	Biological standards for hepatitis B virus assays. <i>Journal of Hepatology</i> , 1992, 15, 251-255.	3.7	6

#	ARTICLE	IF	CITATIONS
181	Preoperative serum levels of wild-type and hepatitis B e antigen-negative hepatitis B virus (HBV) and graft infection after liver transplantation for HBV-related hepatocellular carcinoma. <i>Journal of Viral Hepatitis</i> , 1997, 4, 235-242.	2.0	6
182	Molecular analysis of VHL+ B lymphocytes in hepatitis C patients. <i>Digestive and Liver Disease</i> , 2003, 35, 788-794.	0.9	6
183	Animal model for liver cell banking from non-heart beating donors after prolonged ischaemia time. <i>Digestive and Liver Disease</i> , 2006, 38, 905-911.	0.9	6
184	Do the circulating Preâ€S/S quasispecies influence hepatitis B virus surface antigen levels in the HBeAg negative phase of HBV infection?. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 1406-1416.	3.7	6
185	Hepatitis B virus replication modulates pathogenesis of hepatitis D virus in chronic hepatitis D. <i>Hepatology</i> , 1991, 13, 413-416.	7.3	6
186	Management and Treatment of Patients with Chronic Hepatitis B: Towards Personalized Medicine. <i>Viruses</i> , 2022, 14, 701.	3.3	6
187	Long-term response to interferon-alfa 2b re-treatment in chronic hepatitis C. <i>Journal of Hepatology</i> , 1994, 21, 278-279.	3.7	5
188	The prevalence of hepatitis C virus types in patients of the same geographic area, according to the source of infection and liver disease. <i>Clinical and Diagnostic Virology</i> , 1997, 8, 189-194.	1.7	5
189	Hepatitis B virus replication and clinical outcome in carriers of HBsAg. Perspectives of treatment with DNA inhibitors. <i>Liver</i> , 1983, 3, 30-35.	0.1	5
190	Personalized therapy in chronic viral hepatitis. <i>Molecular Aspects of Medicine</i> , 2008, 29, 103-111.	6.4	5
191	From Actors to Authors. <i>Journal of Ambulatory Care Management</i> , 2010, 33, 231-240.	1.1	5
192	A cost-effectiveness model to personalize antiviral therapy in naive patients with genotype 1 chronic hepatitis C. <i>Digestive and Liver Disease</i> , 2015, 47, 249-254.	0.9	5
193	Maturation of the Visceral (Gut-Adipose-Liver) Network in Response to the Weaning Reaction versus Adult Age and Impact of Maternal High-Fat Diet. <i>Nutrients</i> , 2021, 13, 3438.	4.1	5
194	Asymptomatic anti-HCV seropositive subjects include patients with chronic active hepatitis and individuals with normal liver: can we distinguish them?. <i>Journal of Hepatology</i> , 1994, 21, 136-137.	3.7	4
195	Is Hepatitis C Virus RNA Detectable in Dialysis Ultrafiltrate?. <i>Nephron</i> , 1996, 72, 102-103.	1.8	4
196	Tailoring interferon dose and monitoring viral load in hepatitis C virus genotype 1b infected patients: a pilot study. <i>Digestive and Liver Disease</i> , 2000, 32, 211-216.	0.9	4
197	Optimization of in vitro HBV replication and HBsAg production in HuH7 cell line. <i>Journal of Virological Methods</i> , 2013, 189, 110-117.	2.1	4
198	Introduction to â€Hepatitis B virus heterogeneity â€ a means to personalized careâ€™. <i>Antiviral Therapy</i> , 2010, 15, 1-2.	1.0	4

#	ARTICLE	IF	CITATIONS
199	The immunological diagnosis of HBsAg liver disease by combined screening for three systems in the serum and the HB core and surface antigens in liver biopsy samples. <i>Research in Clinic and Laboratory</i> , 1977, 7, 365-372.	0.3	4
200	Possible immunopathogenesis for fibrosing cholestatic hepatitis. <i>Gastroenterology</i> , 1994, 106, 822-823.	1.3	3
201	Demonstration of specific detection of anti-HCV IgM core antibodies. <i>Journal of Virological Methods</i> , 1996, 59, 121-126.	2.1	3
202	Usefulness of IgM anti-HCV in differential diagnosis between recurrent hepatitis C and acute rejection in liver transplant patients. <i>Transplantation Proceedings</i> , 2001, 33, 3641-3642.	0.6	3
203	Clinical significance of the antibody to the putative core protein of hepatitis C virus in patients with chronic liver disease. <i>Liver</i> , 1993, 13, 222-226.	0.1	3
204	Reply to: "To target or not to target viral antigens in HBV related HCC". <i>Journal of Hepatology</i> , 2015, 62, 1450-1452.	3.7	3
205	Modeling Hepatocellular Carcinoma Cells Dynamics by Serological and Imaging Biomarkers to Explain the Different Responses to Sorafenib and Regorafenib. <i>Cancers</i> , 2021, 13, 2064.	3.7	3
206	Evidence of a Gastro-Duodenal Effect on Adipose Tissue and Brain Metabolism, Potentially Mediated by Gut Liver Inflammation: A Study with Positron Emission Tomography and Oral 18F-FDG in Mice. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2659.	4.1	3
207	Normal lymphocyte interferon production in adult HBsAg-positive chronic active liver disease. <i>Journal of Medical Virology</i> , 1979, 4, 43-50.	5.0	2
208	Delta and non-A, non-B hepatitis viruses. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 1988, 7, 327-336.	2.9	2
209	Rabbit-derived anti-HD antibodies for HDAg immunoblotting. <i>Journal of Hepatology</i> , 1991, 13, S130-S133.	3.7	2
210	Safety of anti-HCV-reactive immunoglobulin in heart transplant patients. <i>Lancet, The</i> , 1992, 340, 1039.	13.7	2
211	Expression of the c-myc protooncogene product in cells infected with the hepatitis delta virus. <i>Hepatology</i> , 1994, 20, 1109-1114.	7.3	2
212	Hepatitis C virus infection in patients with haematological diseases: evidence for the association with erythrocytes transfusion and liver disease. <i>International Hepatology Communications</i> , 1995, 4, 9-15.	0.7	2
213	Living-donor liver transplantation: to be or not to be. <i>Digestive and Liver Disease</i> , 2000, 32, 243-244.	0.9	2
214	Impact of antiviral treatment on recurrence of hepatitis B virus infection and disease. <i>Transplantation Proceedings</i> , 2003, 35, 1028-1029.	0.6	2
215	Pathogenesis of Chronic Hepatitis B. <i>J Hepatol</i> , 2000, 32, 308-322.		2
216	The impact of molecular biology in the diagnosis and management of viral hepatitis. <i>Research in Clinic and Laboratory</i> , 1988, 18, 261-271.	0.3	1

#	ARTICLE	IF	CITATIONS
217	The hepatitis C virus carrier with "persistently" normal serum transaminases: a misleading clinical issue. <i>Digestive and Liver Disease</i> , 2000, 32, 603-604.	0.9	1
218	Validation and comparison of different PCR-based methods for detection of hepatitis B virus precore region mutants. <i>Journal of Virological Methods</i> , 2005, 129, 64-74.	2.1	1
219	Software and expert system for the management of chronic hepatitis B. <i>Journal of Clinical Virology</i> , 2005, 34, S29-S33.	3.1	1
220	A Deep Learning Approach for Hepatic Steatosis Estimation from Ultrasound Imaging. <i>Communications in Computer and Information Science</i> , 2021, , 703-714.	0.5	1
221	Hepatitis B Virus Precore Mutants. , 1994, , 256-260.		1
222	Maternal High-Fat Feeding Affects the Liver and Thymus Metabolic Axis in the Offspring and Some Effects Are Attenuated by Maternal Diet Normalization in a Minipig Model. <i>Metabolites</i> , 2021, 11, 800.	2.9	1
223	Different Kinetics of HBV-DNA and HBsAg in HCV Coinfected Patients during DAAs Therapy. <i>Journal of Clinical Medicine</i> , 2022, 11, 1406.	2.4	1
224	Interferon treatment of chronic hepatitis B surface antigen (HBsAg) carriers. A description of the activation profiles of natural killer cells obtained with different schedules of administration in three subsets of carriers. <i>Research in Clinic and Laboratory</i> , 1987, 17, 331-341.	0.3	1
225	Antibodies against the human pancreas in acute and chronic liver disease. <i>Research in Clinic and Laboratory</i> , 1975, 5, 146-158.	0.3	1
226	Nucleic acid hybridization in viral Hepatitis research. <i>Research in Clinic and Laboratory</i> , 1988, 18, 121-142.	0.3	0
227	Application Of Nucleic acid hybridization to the hepatitis B virus research. <i>Research in Clinic and Laboratory</i> , 1988, 18, 143-160.	0.3	0
228	Chronic viral hepatitis. <i>Journal of Hepatology</i> , 1991, 13, S27-S30.	3.7	0
229	Use of interferon in chronic viral hepatitis.. <i>Pharmacological Research</i> , 1992, 26, 96-97.	7.1	0
230	Prediction of relapse or sustained response in biochemical responders by serum hepatitis C virus RNA monitoring during interferon therapy. <i>Journal of Viral Hepatitis</i> , 1999, 6, 373-380.	2.0	0
231	The Impact of Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV): From Research to Clinical Practice. , 2000, 45, 99-112.		0
232	Foreword. <i>Transplantation Proceedings</i> , 2000, 32, 2691-2692.	0.6	0
233	Hepatitis C virus infection: early diagnosis and identification of response to antiviral therapy. <i>Expert Review of Molecular Diagnostics</i> , 2001, 1, 310-314.	3.1	0
234	Colorectal cancer. A novel approach to adjuvant chemotherapy with fluoropyrimidines. <i>Digestive and Liver Disease</i> , 2002, 34, 396-397.	0.9	0

#	ARTICLE	IF	CITATIONS
235	Liver transplantation in genetic defects of hepatocytes. Transplantation Proceedings, 2003, 35, 1049.	0.6	0
236	Horse antilymphocytic globulin in hepatitis B exacerbation after bone marrow transplantation adoptive immunity transfer. Bone Marrow Transplantation, 2004, 33, 1057-1059.	2.4	0
237	Dianostic tools from molecular biology. Liver, 1992, 12, 213-216.	0.1	0
238	Conclusion to "Hepatitis B virus heterogeneity" a means to personalized care™. Antiviral Therapy, 2010, 15, 79-80.	1.0	0
239	Occult Hepatitis B Virus (HBV) Infections: Hepatitis B Surface Antigen (HBsAg) Negative and Primary Occult. Current Hepatitis Reports, 2013, 12, 112-118.	0.3	0
240	Impatto sul budget di un trattamento personalizzato dell'epatite B cronica HBeAg-negativa in Italia mediante peg-interferone alfa-2a associato alla stopping-rule alla 12a settimana. Pharmacoeconomics Italian Research Articles, 2013, 15, 123-130.	0.2	0
241	Variants of hepatitis B virus. Archives of Virology Supplementum, 1992, 4, 83-85.	3.0	0
242	Serology. , 1992, , 128-141.		0
243	Wild-type and HBeAg-minus HBV Fluctuations: Cause or Effect of Chronic Hepatitis B Pathogenic Mechanisms?. , 1994, , 261-264.		0
244	Modeling HCV Dynamics in Clinical Practice to Personalize Antiviral Therapy. , 2016, , 303-321.		0
245	Low <i>Anisakis</i> -specific IgE prevalence in dyspeptic patients in Italy " a retrospective study. The EuroBiotech Journal, 2018, 2, 59-63.	1.0	0
246	On the operational definition of fatty liver. Qeios, 0, , .	0.0	0
247	Effects of Different Scan Projections on the Quantitative Ultrasound-Based Evaluation of Hepatic Steatosis. Healthcare (Switzerland), 2022, 10, 374.	2.0	0
248	Liver and White/Brown Fat Dystrophy Associates with Gut Microbiota and Metabolomic Alterations in 3xTg Alzheimer's Disease Mouse Model. Metabolites, 2022, 12, 278.	2.9	0
249	Hepatitis C virus infection and liver disease: Peculiar epidemiological and clinicopathological features. FEMS Microbiology Reviews, 1994, 14, 259-265.	8.6	0